The E2211 trial showed the longest progression-free survival and highest response rates with temozolomide plus capecitabine reported to date for patients with pancreatic neuroendocrine tumors. Study chair Pamela L. Kunz, MD (Yale University School of Medicine), presented the findings at the 2022 Annual Meeting of the American Society of Clinical Oncology.